Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting

NEW YORK, Nov. 9, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that two abstracts highlighting potential cost savings based on clinical observations from clinical trials of Zerenex™ (ferric citrate) have been accepted for poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2011 Annual Meeting and exposition taking place November 8-13 in Philadelphia.

Friday, November 11, 2011 – Poster #1566

Abstract # 23502, entitled "TSAT and Serum Ferritin Increases Observed in Ferric Citrate Clinical Trials May Lead to Dialysis Cost Savings" will be presented on Friday, November 11, 2011 at 10:00am ET during the "Dialysis: Anemia, Malnutrition, and Metabolism – II" Poster Session, and will be available for viewing from 10:00am-12:00pm ET.

Saturday, November 12, 2011 – Poster #2647

Abstract # 23692, entitled "Physician Reaction to Spontaneous Rises in Transferrin Saturation and Serum Ferritin Levels in End Stage Renal Disease Patients" will be presented on Saturday, November 12, 2011 at 10:00am ET during the "Dialysis: Epidemiology, Outcomes, and Clinical Trials: Non-Cardiovascular – III" Poster Session, and will be available for viewing from 10:00am-12:00pm ET.

The above abstracts are currently available online for viewing through the ASN website at:

The Zerenex Phase 3 registration program, which is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA), is comprised of an already successfully-completed Phase 3 short-term study, and an ongoing Phase 3 long-term study.

Keryx holds a worldwide license (except for certain Asian Pacific countries) to Zerenex (ferric citrate) from Panion & BF Biotech, Inc. The Japanese rights are sublicensed by Keryx to Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.


Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for Zerenex (ferric citrate), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for Zerenex; our ability to meet anticipated development timelines for Zerenex due to clinical trial results, manufacturing capabilities or other factors; our ability to replicate in our ongoing long-term Phase 3 clinical study the efficacy and safety of Zerenex observed in the previous Phase 2 studies and the short-term Phase 3 study, and the effects on intravenous (IV) iron and erythropoiesis-stimulating agent (ESA) use observed in the Phase 2 Open Label Extension study; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at The information on our website, and on the ASN website, is not incorporated by reference into this press release and is included as an inactive textual reference only.

Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
4. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Post Your Comments:
(Date:10/7/2015)... , October 8, 2015 ... Medical biotechnology accounts for largest bioinformatics market ... in drug discovery and development process says ... . --> ... the basis of applications, the bioinformatics market ...
(Date:10/7/2015)... , ... October 07, 2015 , ... ... ) will present a public educational seminar on the latest advances in ... 10th from 1:00 pm – 3:00 pm at the Hilton Dallas/Southlake Town Square ...
(Date:10/7/2015)...   PDI , a leader in infection prevention ... key challenges across various healthcare settings, as well as ... This tool is part of a larger effort to ... efficiencies and lower healthcare-associated infections. ... of how to use the right product, in the ...
(Date:10/7/2015)... , Oct. 7, 2015   Intrexon Corporation ... today announced it will hold an Investor Day in ... afternoon of Thursday, November 12, 2015. Intrexon,s Chairman and ... other members of the Company,s management team as well ... focus on strategic initiatives, product pipeline, and program updates ...
Breaking Biology Technology:
... (Amex: PLX ), announced today that it ... its manufacturing and research,facility. The expanded space, located ... the Company with approximately three times its current,manufacturing ... Company,s lead product candidate, prGCD, a therapeutic protein ...
... The Woodbridge Group announced,the most extensive interior ... "Green" Polyurethane Foams. As a key component ... technology, substitutes petroleum,with plant oils, in the ... a full line-up of automotive interior,applications includes; ...
... Pharmaceuticals,Inc. (NYSE: BRL ) today confirmed that ... of the patent listed by Forest,Laboratories, Inc. in ... 10mg., Barr filed its Abbreviated New Drug ... generic Namenda product with the U.S. Food,& Drug ...
Cached Biology Technology:
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. ... interface solutions, today announced that Lenovo has selected Synaptics ... sensor, FS4202, for its latest smartphone, the Vibe P1. ... access to unlock the device and provide swift access ... The feature-rich Natural ID FS4202 sensor solution utilizes ...
(Date:9/24/2015)... 2015  EyeLock LLC, a market leader of iris-based ... and latest technology in Booth #602 at next week,s ... EyeLock,s iris authentication technology provides an unprecedented ... making it the most proven way to authenticate one,s ... to deliver a fast and friendly user experience to ...
(Date:9/10/2015)... This report provides detailed descriptions of the ... emerging sensor types that will dominate in the future. ... the wearable technology hype curve in the last five ... feature with all of them is the prominence of ... useful functions. Sensors collect data about the physical and ...
Breaking Biology News(10 mins):
... Amsterdam, 16 March, 2011 A recent special edition ... Elsevier, on behalf of the British Mycological Society, features a ... collection of fungal cell biology movies ever published. The movies ... Exeter, UK, who is a renowned researcher in the field ...
... analyze the complex ingredients in the new genre of ... for cigarettes in places where smoking is banned have ... The report appears in ACS,s Journal of Agricultural ... colleagues point out that the first dissolvable tobacco products ...
... Trends in Plant Science , provides an overview ... for ecologists, physiologists and molecular biologists, since it covers ... change. The results show that plants in ... to a changing environment without requiring any evolutionary changes, ...
Cached Biology News:
... 20 Plasma Immunodepletion Kit specifically removes 20 ... plasma or serum in preparation for further ... into the plasma proteome whether you use ... chromatography or go straight to mass spectrometry. ...
... Since OligoEngine introduced the industry's first ... have constantly strived to keep these tools ... research reports in the field of RNAi. ... enhanced, and expanded RNAi design tools, OligoEngine ...
... for enzyme-/substrate-based blotting what intensifying screens do for ... to 10-fold (or one order of magnitude) in ... Enhancer membrane treatment is a simple, 15-minute procedure ... Western blotting protocol. The result is an increase ...
Biology Products: